Matribhumi Samachar English
Toronto, Ontario and Chicago, Illinois–(Newsfile Corp. – August 5, 2025) – Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that the US Centers for Medicare & Medicaid Services (CMS) has approved New Technology Add-On Payment (NTAP) reimbursement for eligible cases involving the use of GRAFAPEX™ (treosulfan) for Injection …
Read More »Medexus Successfully Completes Agreement for Public Reimbursement of Trecondyv (treosulfan for injection) in Quebec, Canada
Toronto, Ontario and Chicago, Illinois–(Newsfile Corp. – April 17, 2025) – Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) recently completed a listing agreement with the provincial government of Quebec for Trecondyv® (treosulfan for injection). The Public Prescription Drug Insurance Plan of the Régie de l’Assurance Maladie du Québec, or RAMQ, will …
Read More »Medexus Completes Agreement to Return US Commercialization Rights for Gleolan to NX Development Corp.
Toronto, Ontario and Chicago, Illinois–(Newsfile Corp. – March 14, 2025) – Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) recently completed an agreement with NX Development Corp., the licensor of Medexus’s rights to Gleolan® in the United States, to terminate the license, supply, and distribution agreement between the parties and return responsibility …
Read More »Medexus Announces Strong Fiscal Q3 2025 Results, Well-Positioned to Launch GRAFAPEX (treosulfan) for Injection in the United States
Fiscal Q3 2025 revenue of $30.0 million, net income of $0.7 million, operating income of $3.8 million, and Adjusted EBITDA* of $5.8 million Management to host conference call at 8:00 AM Eastern time on Thursday, February 6, 2024 Toronto, Ontario and Chicago, Illinois–(Newsfile Corp. – February 5, 2025) – Medexus …
Read More »Medexus Schedules Third Fiscal Quarter 2025 Conference Call
Toronto, Ontario and Chicago, Illinois–(Newsfile Corp. – January 31, 2025) – Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, February 6, 2025 to discuss Medexus’s results for its third fiscal quarter ended December 31, 2024. Medexus expects to file …
Read More »Medexus Pharmaceuticals Announces Closing of $30 Million Overnight Marketed Public Offering of Common Shares
Toronto, Ontario and Chicago, Illinois–(Newsfile Corp. – January 31, 2025) – Medexus Pharmaceuticals Inc. (TSX: MDP) (“Medexus” or the “Company”), is pleased to announce the closing of its previously announced overnight marketed underwritten offering (the “Offering”) of 7,500,000 common shares of the Company (the “Common Shares”) at a public offering …
Read More »